Read the story here. Advertise at Before It's News here.
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views
Last hour:
Last 24 hours:

Highlight Therapeutics reveals 'potentially game-changing' results from melanoma immunotherapy study

% of readers think this story is Fact. Add your two cents.

Highlight Therapeutics has revealed what it called “potentially game-changing” early results from the Phase 2b clinical trials of its lead drug in combination with a leading immunotherapy drug.

Chief executive Dr Marisol Quintero said the privately-owned company is now in the planning stage of a pivotal Phase 3 trial, due to begin in 2022, and is starting to talk to potential partners about other combinations.

The Phase 2 study is testing Highlight’s BO-112 drug in combination with a leading anti-PD1 immunotherapy as a second-line treatment on 37 melanoma patients who have shown anti-PD1 resistance. In other words, the drug combination is being given to patients who have previously had no success with immunotherapy treatments for their skin cancer.

Highlight said the trial has met its primary endpoint with a 65% disease control rate, where the melanoma is prevented from growing, plus a 27% preliminary overall response rate (ORR) that includes 8% complete responses, where the tumour has reduced in size.

Dr Quintero said: “This initial data is very encouraging and has the potential to change medical practice.”

She said the preliminary ORR and complete responses already exceed current standards of care, such as the use of anti-CTLA-4 immunotherapy.

Some sub-groups of patients also showed notable results, including hard-to-treat mucosal melanoma patients achieving 66% ORR and 100% disease control rate.

Based on the drug’s mode of action and experience from Phase 1 studies, Quintero and the team expect follow-up data from these patients will show further improvements in the ORR by the time full results are published in the spring.

Executive chairman Dr Carlos Paya called the result “potentially game-changing” as they show BO-112 “can rescue melanoma patients who have failed first-line immune-therapy with anti-PD1”.

He added: “Anti-PD1 based immunotherapy has revolutionized oncology treatments, but only a fraction of patients initially respond and many of these patients progress thereafter. These initial Phase 2 results show that BO-112 combined with a leading PD1 inhibitor rescue around 65% of anti-PD1 failing patients, making many of them respond to the combined treatment.

“These much-anticipated outcomes demonstrate BO-112′s potential as a best-in-class therapy for melanoma patients whose disease has progressed on prior anti-PD1 treatment, and we now look forward to further clinical studies, not only in melanoma but in other major tumor types in which anti-PD1 resistance is also an issue.”

The market for anti-PD1 therapies is valued at roughly US$24bn, according to the IQVIA Global Oncology Report, with the drugs used across most solid tumours – although currently fewer than 20% of all cancer patients benefit from first-line anti-PD1 treatment.

BO-112 in combination with an anti-PD1 therapy is designed to ‘resensitize’ tumors to anti-PD1 treatment by a dual action of making the tumour cells more visible to the immune system as well as ‘training’ the body’s T-cells to target the cancer cells.

In this Phase 2 trial, BO-112 is being given in combination with Merck & Co’s (MSD) Keytruda anti-PD1 immunotherapy.

The safety profile of combination has been exemplary, with no patients discontinuing the study due to adverse events.

Story by ProactiveInvestors


Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Please Help Support BeforeitsNews by trying our Natural Health Products below!

Order by Phone at 888-809-8385 or online at M - F 9am to 5pm EST

Order by Phone at 866-388-7003 or online at M - F 9am to 5pm EST

Order by Phone at 866-388-7003 or online at M - F 9am to 5pm EST

Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!

HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation.

Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.

MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)

Oxy Powder - Natural Colon Cleanser!  Cleans out toxic buildup with oxygen!

Nascent Iodine - Promotes detoxification, mental focus and thyroid health.

Smart Meter Cover -  Reduces Smart Meter radiation by 96%! (See Video).

Report abuse


    Your Comments
    Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

    Load more ...




    Email this story
    Email this story

    If you really want to ban this commenter, please write down the reason:

    If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.